XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Price & Overview
NASDAQ:XERS • US98422E1038
Current stock price
The current stock price of XERS is 6.05 USD. Today XERS is up by 1.68%. In the past month the price increased by 8.62%. In the past year, price increased by 40.37%.
XERS Key Statistics
- Market Cap
- 1.043B
- P/E
- N/A
- Fwd P/E
- 53.23
- EPS (TTM)
- -0.01
- Dividend Yield
- N/A
XERS Stock Performance
XERS Stock Chart
XERS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to XERS. When comparing the yearly performance of all stocks, XERS turns out to be only a medium performer in the overall market: it outperformed 59.13% of all stocks.
XERS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XERS. There are concerns on the financial health of XERS while its profitability can be described as average.
XERS Earnings
On March 2, 2026 XERS reported an EPS of 0.06 and a revenue of 85.81M. The company beat EPS expectations (33.69% surprise) and beat revenue expectations (2.17% surprise).
XERS Forecast & Estimates
13 analysts have analysed XERS and the average price target is 11.37 USD. This implies a price increase of 87.86% is expected in the next year compared to the current price of 6.05.
For the next year, analysts expect an EPS growth of 1236.59% and a revenue growth 33.39% for XERS
XERS Groups
Sector & Classification
XERS Financial Highlights
Over the last trailing twelve months XERS reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 97.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.19% | ||
| ROA | 0.14% | ||
| ROE | 4.05% | ||
| Debt/Equity | 16.1 |
XERS Ownership
XERS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 25.28 | 867.014B | ||
| JNJ | JOHNSON & JOHNSON | 17.93 | 555.546B | ||
| MRK | MERCK & CO. INC. | 21.98 | 283.098B | ||
| PFE | PFIZER INC | 9.03 | 151.709B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.27 | 120.503B | ||
| ZTS | ZOETIS INC | 16.52 | 48.806B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.56 | 28.639B | ||
| VTRS | VIATRIS INC | 5.85 | 17.175B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.62 | 11.181B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.346B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.169B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.097B | ||
| CORT | CORCEPT THERAPEUTICS INC | 84.88 | 4.795B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XERS
Company Profile
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 435 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Company Info
IPO: 2018-06-21
XERIS BIOPHARMA HOLDINGS INC
1375 West Fulton Street, Suite 1300
Chicago ILLINOIS 60601 US
CEO: Paul R. Edick
Employees: 435
Phone: 18444455704
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
Can you describe the business of XERIS BIOPHARMA HOLDINGS INC?
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 435 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
What is the stock price of XERIS BIOPHARMA HOLDINGS INC today?
The current stock price of XERS is 6.05 USD. The price increased by 1.68% in the last trading session.
What is the dividend status of XERIS BIOPHARMA HOLDINGS INC?
XERS does not pay a dividend.
What is the ChartMill technical and fundamental rating of XERS stock?
XERS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the market capitalization of XERS stock?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a market capitalization of 1.04B USD. This makes XERS a Small Cap stock.
When does XERIS BIOPHARMA HOLDINGS INC (XERS) report earnings?
XERIS BIOPHARMA HOLDINGS INC (XERS) will report earnings on 2026-05-07.